First, do no harm: Evaluating clinical skills for patient safety in oncology fellows.

E Ernesto Gil Deza (Instituto Oncológico Henry Moore, Buenos Aires, Argentina) L Lourdes Gil Deza (Instituto Oncologico Henry Moore, Caba, Argentina) M Mariana Abal (Instituto Oncologico Henry Moore, Capital Federal, Buenos Aires, Argentina) C Carlos Garcia Gerardi (Instituto Oncológico Henry Moore, Buenos Aires, Argentina) F Flavio A. Tognelli (Henry Moore Institute, Caba, Argentina) I Isaias Gil Deza (Instituto Oncológico Henry Moore, Buenos Aires, Argentina) L Leonel Antonio Smolje (Instituto Oncológico Henry Moore, Buenos Aires, Argentina) L Luis Pizarro (Instituto Oncológico Henry Moore, Buenos Aires, Argentina) S Santiago Nicolás Veleda (Instituto Oncológico Henry Moore, Caba, Argentina) G Gaston Martin Reinas (Instituto Oncologico Henry Moore, Ciudad De Buenos Aires, Argentina) M Mario Javier Nacul (Instituto Oncológico Henry Moore, Caba, Argentina) D Daniel Rampa (Instituto Oncológico Henry Moore, Caba, Argentina) A Alberto Rancati (Instituto Oncológico Henry Moore, Caba, Argentina) M Martin Eleta (Imaxe, Buenos Aires, Argentina) C Claudia Lorena Acuna (Instituto Oncologico Henry Moore, Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina) M María del Huerto Jaunarena (Universidad del Salvador, Caba, Argentina) M María del Carmen Bacqué (Universidad del Salvador, Caba, CABA, Argentina) D Daniela Gercovich (Henry Moore Institute, Buenos Aires, Argentina)

Abstract

e21009 Background: This study aims to present the results and design of the Observational Standardized Clinical Examination (JCO 34, e18150, 2016) IOHM-USAL 2024, which focused on evaluating the clinical skills necessary to ensure patient safety. Methods: The clinical skills essential for patient safety were assessed through a series of stations. At each station, trained observers were present to evaluate the fellows' performance and complete an evaluation form. The stations were: a) Biosecurity in drug preparation (including hand washing, proper use of disposable clothing and gloves, and drug identification), b) Laboratory assessment prior to chemotherapy or immunotherapy administration, c) Drug administration via IV catheter, d) Management of chemotherapy extravasation, e) Evaluation of clinical response in a model of breast nodules, f) Detection of errors in different medical images, and g) Conflict de-escalation in a consultation with an aggressive patient. Results: Fourteen oncology fellows were evaluated. The outcomes for each station were as follows: a) Four out of 14 (28%) did not adhere to biosecurity guidelines. b) One out of 14 (7%) authorized chemotherapy administration without adequate laboratory results. c) All fellows successfully administered the drug via IV catheter. d) One out of 14 (7%) mishandled doxorubicin extravasation. e) Six out of 14 (42%) incorrectly assessed the clinical response in breast nodules. f) Three out of 14 (21%) failed to detect errors in medical images. g) Six out of 14 (42%) were unable to de-escalate a conflict during a consultation. Conclusions: A) Clinical skills essential for patient safety can be effectively evaluated through an Observational Standardized Clinical Examination (OSCE). B) In this implementation, medical errors were identified in biosecurity practices, laboratory assessments, clinical evaluations, and image interpretation. Only one student mishandled chemotherapy extravasation, and nearly half of the students struggled with conflict de-escalation during a consultation. C) This exam serves as a valuable tool for identifying both strengths and weaknesses in oncology fellows, allowing for targeted training to address specific gaps in knowledge and skills. D) Addressing these shortcomings in medical education is critical to ensure patient safety.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

E

Ernesto Gil Deza

Instituto Oncológico Henry Moore, Buenos Aires, Argentina

L

Lourdes Gil Deza

Instituto Oncologico Henry Moore, Caba, Argentina

M

Mariana Abal

Instituto Oncologico Henry Moore, Capital Federal, Buenos Aires, Argentina

C

Carlos Garcia Gerardi

Instituto Oncológico Henry Moore, Buenos Aires, Argentina

F

Flavio A. Tognelli

Henry Moore Institute, Caba, Argentina

I

Isaias Gil Deza

Instituto Oncológico Henry Moore, Buenos Aires, Argentina

L

Leonel Antonio Smolje

Instituto Oncológico Henry Moore, Buenos Aires, Argentina

L

Luis Pizarro

Instituto Oncológico Henry Moore, Buenos Aires, Argentina

S

Santiago Nicolás Veleda

Instituto Oncológico Henry Moore, Caba, Argentina

G

Gaston Martin Reinas

Instituto Oncologico Henry Moore, Ciudad De Buenos Aires, Argentina

M

Mario Javier Nacul

Instituto Oncológico Henry Moore, Caba, Argentina

D

Daniel Rampa

Instituto Oncológico Henry Moore, Caba, Argentina

A

Alberto Rancati

Instituto Oncológico Henry Moore, Caba, Argentina

M

Martin Eleta

Imaxe, Buenos Aires, Argentina

C

Claudia Lorena Acuna

Instituto Oncologico Henry Moore, Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina

M

María del Huerto Jaunarena

Universidad del Salvador, Caba, Argentina

M

María del Carmen Bacqué

Universidad del Salvador, Caba, CABA, Argentina

D

Daniela Gercovich

Henry Moore Institute, Buenos Aires, Argentina